BioNTech SE ADR (BNTX)

NASDAQ: BNTXHealthcareBiotechnologyUSD

95.25-0.48 (-0.50%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

After hours: 96.00 +0.79%

BNTX stock chart

Technical analysis

Key statistics

All statistics

Market cap: $23.93B
P/E (TTM): —
Forward P/E: —
EPS (TTM): -$7.83
Dividend yield: None
Ex-dividend date: Jun 2, 2022
52-week range: 79.52 – 124.00
Day range: 93.92 – 97.46
Volume / Avg: 827.75K / 1.15M
Beta: —
Shares outstanding: 251.20M
Next earnings: Nov 3, 2026

52-week range

$79.52$124.00

BNTX stock today

Shares of BioNTech (BNTX) finished lower on Oct 7 at $95.25, a drop of 0.50% or $0.48 per share, versus the S&P 500's 0.22% decline. At this level, BNTX sits in the middle of its 52-week range of $79.52 to $124.00: 23.2% below the high, set on Jan 22, 2026 and 19.8% above the low. BNTX is up 1.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 9.4%.

BioNTech has posted a net loss over the last twelve months (EPS of -$7.83), so its P/E ratio is not meaningful. BioNTech's next earnings report is expected on Nov 3, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About BioNTech

Company profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Ugur Sahin M.D.
Headquarters: Mainz
Employees: 7,807
IPO year: 2019
Website: biontech.de

Analyst forecast

Forecast

Consensus (20 analysts)

buy

Avg. price target

$115.79+21.56%

Strong buy 1
Buy 13
Hold 5
Sell 0
Strong sell 1

Target range

Low $73.03High $139.32

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history

Next report: Nov 3, 2026
EPS estimate: $0.82

Dividends

Dividend history

Annual dividend: $0.00
Dividend yield: —
Last payment: $2.11
Ex-dividend date: Jun 2, 2022

BNTX news

All BNTX news

BioNTech peers

Healthcare sector

BNTX peer companies
Company	Price	% Chg	Market cap	P/E	Compare
ROIVRoivant Sciences Ltd.	34.75	-2.20%	$25.10B	—	vs BNTX
INCYIncyte Corp.	113.44	+0.63%	$22.99B	14.5	vs BNTX
GMABGenmab A/S ADS	36.65	-3.04%	$22.54B	29.6	vs BNTX
INSMInsmed Incorporated	101.74	-3.32%	$22.22B	—	vs BNTX
ALNYAlnylam Pharmaceuticals Inc.	224.41	+0.21%	$30.03B	37.8	vs BNTX
RPRXRoyalty Pharma plc Class A	56.76	+0.57%	$32.80B	30.2	vs BNTX
ASNDAscendis Pharma A/S	228.41	+1.04%	$15.03B	17.5	vs BNTX
JAZZJazz Pharmaceuticals plc	231.19	-0.09%	$15.01B	15.8	vs BNTX

Indexes, lists and sector

Appears in lists

Largest Healthcare stocks

BioNTech stock FAQ

What is BioNTech's stock price today?

BNTX last traded at $95.25 as of Oct 7, 4:00 PM EDT, down 0.50% on the day. Prices are delayed at least 15 minutes.

Does BioNTech pay a dividend?

Yes. BioNTech pays $0.00 per share annually. The most recent dividend of $2.11 had an ex-dividend date of Jun 2, 2022.

When is BioNTech's next earnings date?

BioNTech is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.82.

Who is BioNTech's CEO?

Dr. Ugur Sahin M.D. is the chief executive officer of BioNTech SE ADR, which has about 7,807 employees.

What is the BNTX 52-week high?

The 52-week high for BNTX is $124.00 and the 52-week low is $79.52. The stock is currently 23.2% below its high.